Abstract
The importance of Akt, Erk, and their downstream effectors-mediated signaling is indisputable for the proliferation of cell. Growth factor-induced activation of Akt and Erk pathways interacts with each other to regulate proliferation. However, an instructive model, wiring the crucial signaling nodes working in cellular growth and division, is still absent or controversial. Although growth factor-mediated mTORC1 regulation is defined considerably, debates still exist formTORC2. TSC1-TSC2 complex integrates both nutrient and mitogenic signals coming from growth factor receptors. Growth factor-induced PI3K/Akt- and Ras/Erk-mediated TSC2 inhibition is well defined. However, the interaction between TSC complex and new molecules such as Pin1 and DAPK requires further clarifications. Furthermore, the Wnt-β-catenin signaling pathway also intersects with the growth factor signaling at TSC1/TSC2 junction. Therefore, the aim of this perspective paper is to suggest an integrated model, linking growth factor-activated crucial signaling nodes in order to supply key molecular connections to degenerative diseases.
Keywords: Akt, β-catenin, Erk, E2F1, DAPK, GSK3, mTORC1, mTORC2, Pin1, Wnt
Current Molecular Medicine
Title:An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network
Volume: 13 Issue: 1
Author(s): A. Erol
Affiliation:
Keywords: Akt, β-catenin, Erk, E2F1, DAPK, GSK3, mTORC1, mTORC2, Pin1, Wnt
Abstract: The importance of Akt, Erk, and their downstream effectors-mediated signaling is indisputable for the proliferation of cell. Growth factor-induced activation of Akt and Erk pathways interacts with each other to regulate proliferation. However, an instructive model, wiring the crucial signaling nodes working in cellular growth and division, is still absent or controversial. Although growth factor-mediated mTORC1 regulation is defined considerably, debates still exist formTORC2. TSC1-TSC2 complex integrates both nutrient and mitogenic signals coming from growth factor receptors. Growth factor-induced PI3K/Akt- and Ras/Erk-mediated TSC2 inhibition is well defined. However, the interaction between TSC complex and new molecules such as Pin1 and DAPK requires further clarifications. Furthermore, the Wnt-β-catenin signaling pathway also intersects with the growth factor signaling at TSC1/TSC2 junction. Therefore, the aim of this perspective paper is to suggest an integrated model, linking growth factor-activated crucial signaling nodes in order to supply key molecular connections to degenerative diseases.
Export Options
About this article
Cite this article as:
Erol A., An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network, Current Molecular Medicine 2013; 13 (1) . https://dx.doi.org/10.2174/1566524011307010086
DOI https://dx.doi.org/10.2174/1566524011307010086 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges
Current Medicinal Chemistry Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design Histone Acetylation / Deacetylation and Cancer: An “Open” and “Shut” Case?
Current Molecular Medicine Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications
Medicinal Chemistry Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Histone Deacetylase Inhibition: A Differentiation Therapy for Cultured Primary Hepatocytes?
Current Enzyme Inhibition In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Genetics, Gene Expression, and Targeted Therapies in Chronic Lymphocytic Leukemia
Current Drug Targets The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment
Current Medicinal Chemistry Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Cytosine Methyltransferases as Tumor Markers
Current Genomics Medulloblastoma: Role of Developmental Pathways, DNA Repair Signaling, and Other Players
Current Molecular Medicine Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery